Our story started over 30 years ago, when Dr. Malcolm Brenner, our co-founder, and his team at Baylor College of Medicine embarked on a journey to better understand and harness the body’s natural anti-viral immune response as a therapy for cancer treatment. Their research has led to several clinical studies investigating the use of a type of immune cells, known as Virus-Specific T cells (VSTs) against cancer. These studies have shown early efficacy and a strong safety profile in cancer patients.
Leveraging these promising data, a Phase II clinical trial for TT10 – a VST therapy targeting nasopharyngeal cancer (NPC) at the National Cancer Centre Singapore (NCCS) was initiated. The study produced the best published 2-year survival data in patients with advanced NPC. The trial results set the stage for a Phase III trial – and it is the world’s largest T cell therapy trial for any cancer indications with 330 patients from 30 hospitals across 5 countries.
Today, Tessa Therapeutics is building a portfolio of next-generation cell therapies targeting a wide range of cancer indications. We are proud to be innovators in the field of cancer immunotherapy, and remain committed to making a difference in the lives of cancer patients worldwide.
Our T cell therapies harness the power of the immune system, train it to recognize cancer cells and eliminate them. Building on this scientific platform, Tessa Therapeutics is developing a portfolio of next-generation autologous and allogeneic cell therapies by combining T cells with other immuno-oncology approaches.
We are also creating a novel, allogeneic platform technology by integrating the properties of CD30-Chimeric Antigen Receptors (CD30-CARs) and Virus-Specific T cells in an allogeneic setting. This technology has the potential to create next-generation, off-the-shelf cell therapies to fight against a wider range of hematological malignancies and solid tumors. At its core, Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CARs technology to increase efficacy – and encouraging preclinical/early clinical data demonstrate the promise of this scientific approach.
Our clinical pipeline includes two innovative cell therapy platforms: CD30-CARs and VSTs. Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphoma.
Building robust, scalable operational capabilities is a critical aspect of our strategy to rapidly and reliably deliver cell therapies to patients worldwide.
Bolstered by a global production and supply chain footprint and a strong clinical trial network, our cell therapies have been delivered to patients in 30 clinical sites across 5 countries. To date, we have successfully delivered over 150 autologous cell therapies in a Phase III clinical trial setting.
Tessa Therapeutics plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in 2021. Located in Singapore, it will be one of the leading facilities of its kind in Asia. The state-of-the-art facility is designed to fulfil multiple cell therapy trials on a global scale.
The facility will run both clinical and commercial manufacturing of cell therapy products that are compliant with current Good-Manufacturing-Practice (cGMP) guidelines from the U.S. Food and Drug Administration, European Medicines Agency and key regulators in Asia.
Clinical Trial Network
Together with our academic, clinical, and scientific research partners, we have established a fully integrated approach for the treatment of cancer with immunotherapy.
Our clinical trial partners include leading institutions in the United States, such as the Baylor College of Medicine, Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center, Baylor Scott & White Health, as well as other Centers of Excellence in Massachusetts, Texas, and California.